Obesite tedavisinde üç aylık dexfenfluramine (dF) kullanımının sonuçları
Küçük Resim Yok
Tarih
1998
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Bu çalışmaya daha önceleri diyet yapmaya çalışarak kilo verememiş olan 61 obez hasta alındı. BMI (body mass index)' leri 26.02 - 54.86 (mean 35.37 ± 6.16), yaşları 19 ve 62 arasında idi (mean 41.0 ± 4.3). Hastalara kaloriden kısıtlı diyet ve günde iki kez 15 mg dF verildi. Hastaların dört tanesinde tedavi yan etkiler nedeni ile durduruldu (bunların birinde depresyon, birinde migren ataklarında sıklaşma, birinde hipertansiyonda labilite ve sonuncuda ise konstipasyon gelişti). 57 hasta çalışmayı tamamladı. Tedavinin 0, 4, 8, 12. haftalarında vücut ağırlığı, BM!, arteriyel kan basıncı, yan etkiler ve laboratuvar parametreleri kaydedildi. dF kullandığımız hastalarda istatistilcsel olarak anlamlı miktarda kilo kaybı oldu (p<0.001). Takib edilen serum lipid profilinde de istatistiksel anlamlılık gösteren iyileşmeler oldu (p<0.001). Sonuç olarak, dF serum lipid profili üzerine yararlı etkileri olan başarılı bir anorektik ajandır. Yan etkilere bağlı ilaç bırakım oranı yalnızca % 6.55' dir.
Sixtyone obese patients who could not lose weight in previous months, even though they had diet, were included to this study. BMI (body mass index) were between 26.02 - 54.86 (mean 35.37 ± 6.16), ages were between 19 and 62 (mean 41.0 ± 4.3). They were put on caloric restricted'diet and received dF 15 mg twice a day. Four of them stopped the treatment because of side effects (one had depression, one had frequent migrain attacks, one had labile hypertension and last one was suffered from constipation). 57 patients completed the study. Body weight, BMI Ih arterial blood pressure, side effects, laboratory parameters were assesed at 0, 4, 8, 12 week of the treatment. The patients who were used dF showed statistically significant weight lose. The serum lipids levels in following cantrol evaluations were also showed statistically significant changes. In conclusion dF is a succesful anorectic agent and has beneflcal effects on serum lipid profiles. The side effects that would cause to drop out is only 6.55 %.
Sixtyone obese patients who could not lose weight in previous months, even though they had diet, were included to this study. BMI (body mass index) were between 26.02 - 54.86 (mean 35.37 ± 6.16), ages were between 19 and 62 (mean 41.0 ± 4.3). They were put on caloric restricted'diet and received dF 15 mg twice a day. Four of them stopped the treatment because of side effects (one had depression, one had frequent migrain attacks, one had labile hypertension and last one was suffered from constipation). 57 patients completed the study. Body weight, BMI Ih arterial blood pressure, side effects, laboratory parameters were assesed at 0, 4, 8, 12 week of the treatment. The patients who were used dF showed statistically significant weight lose. The serum lipids levels in following cantrol evaluations were also showed statistically significant changes. In conclusion dF is a succesful anorectic agent and has beneflcal effects on serum lipid profiles. The side effects that would cause to drop out is only 6.55 %.
Açıklama
Anahtar Kelimeler
Genel ve Dahili Tıp
Kaynak
Medical Network Klinik Bilimler ve Doktor
WoS Q Değeri
Scopus Q Değeri
Cilt
4
Sayı
5
